# US 10,863,756 B2 · Method of preventing obesity and cardiovascular problems in poultry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,863,756 B2
- Document ID: US10863756B2
- Status: Granted
- Kind: B2
- Application number: 15/542,143
- Filed: 2016-01-15
- Published: 2018-09-20
- Granted: 2020-12-15
- Earliest claimed: 2015-01-15
- Assignees: Dsm IP Assets B.V.
- Applicants: DSM IP Assets B.V.
- Inventors: Shuen Ei Chen; Thau Kiong Chung
- Web page: https://patentgrep.com/patent/US10863756B2

## CPC

- A23K 20/174: Vitamins
- A23K 20/179: Colouring agents, e.g. pigmenting or dyeing agents
- A23K 20/30: {Oligoelements}
- A23K 50/10: for ruminants
- A23K 50/42: Dry feed
- A23K 50/48: Moist feed
- A23K 50/75: for poultry
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/01: Hydrocarbons
- A61K 31/015: carbocyclic
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/4188: condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
- A61K 31/4415: Pyridoxine, i.e. Vitamin B6 (pyridoxal phosphate A61K31/675)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 31/51: Thiamines, e.g. vitamin B1
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/525: Isoalloxazines, e.g. riboflavins, vitamin B2
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/26: Iron; Compounds thereof
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 39/00: General protective or antinoxious agents
- A23K: FODDER
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a feed for ameliorating weight gain in poultry comprising 25-hydroxy vitamin D, canthaxanthin, Vitamin E and Vitamin C. Animals fed this composition gained weight, but did not become obese, nor did they experience adverse effects associated with hyperphagia related obesity. This feed also provides numerous cardiovascular benefits.

## Claims

### Claim 1

A method of controlling obesity in vitamin replete poultry and/or providing a cardiovascular benefit to vitamin replete poultry comprising administering a composition comprising a combination of 25-hydroxy vitamin D, canthaxanthin, Vitamin E and Vitamin C to the vitamin replete poultry which are fed ad libitum, and wherein the cardiovascular benefit is at least one benefit selected from the group consisting of:
a) clearance of non-esterified fatty acids;
b) amelioration of plasma dyslipidemia;
c) amelioration of triglyceride and ceraminde accumulation in the liver, leg, breast muscle, and heart;
d) suppression of a tissue pro-inflammatory IL-1β production and plasma IL-6 concentration;
e) cardiac protection and enhanced cardiac function through an up-regulation of phosphorylation of STAT-3 in the heart;
f) suppression of an infiltration of immune cells into the heart;
g) decreasing an incidence of ascites;
h) decreasing an incidence of sudden death in a flock due to cardiovascular problems;
i) decreasing an incidence of cardiac morbidities selected from the group consisting of dilation, pericardial effusion, and rupture;
j) decreasing an amount of irregular incidence of ECG patterns;
k) decreasing an occurrence of arrhythmias;
l) ameliorating cardiac fibrosis;
m) ameliorating chronic systemic inflammation; and
n) ameliorating cardiac cell apoptosis.

### Claim 2 (depends on 1)

The method according to claim 1, additionally comprising administering at least one further bio-active ingredient selected from the group consisting of: Vitamin D, Vitamin B2, Vitamin B6, Niacin, Pantothenic Acid, Folic Acid, Biotin, Zinc, Copper, Manganese, Selenium, and combinations thereof.